|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL1R2 |
Gene summary for IL1R2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL1R2 | Gene ID | 7850 |
| Gene name | interleukin 1 receptor type 2 | |
| Gene Alias | CD121b | |
| Cytomap | 2q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | P27930 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7850 | IL1R2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.34e-09 | 7.02e-01 | -0.1808 |
| 7850 | IL1R2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.66e-12 | 5.45e-01 | -0.1954 |
| 7850 | IL1R2 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.50e-04 | 1.07e+00 | -0.2602 |
| 7850 | IL1R2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 8.02e-07 | 9.57e-01 | -0.2196 |
| 7850 | IL1R2 | HTA11_83_2000001011 | Human | Colorectum | SER | 8.15e-07 | 5.35e-01 | -0.1526 |
| 7850 | IL1R2 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.30e-03 | 2.67e-01 | -0.1464 |
| 7850 | IL1R2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 4.88e-03 | 6.85e-01 | -0.1706 |
| 7850 | IL1R2 | A015-C-106 | Human | Colorectum | FAP | 3.61e-02 | -8.05e-02 | -0.0511 |
| 7850 | IL1R2 | LZE2T | Human | Esophagus | ESCC | 3.10e-03 | 1.44e+00 | 0.082 |
| 7850 | IL1R2 | LZE4T | Human | Esophagus | ESCC | 1.81e-02 | -5.84e-01 | 0.0811 |
| 7850 | IL1R2 | LZE20T | Human | Esophagus | ESCC | 3.05e-06 | -6.82e-01 | 0.0662 |
| 7850 | IL1R2 | LZE24T | Human | Esophagus | ESCC | 3.50e-09 | -6.71e-01 | 0.0596 |
| 7850 | IL1R2 | LZE22D3 | Human | Esophagus | HGIN | 1.44e-09 | 5.86e-01 | 0.0653 |
| 7850 | IL1R2 | P1T-E | Human | Esophagus | ESCC | 4.27e-03 | -5.49e-01 | 0.0875 |
| 7850 | IL1R2 | P4T-E | Human | Esophagus | ESCC | 7.75e-13 | -5.65e-01 | 0.1323 |
| 7850 | IL1R2 | P5T-E | Human | Esophagus | ESCC | 4.16e-22 | -6.77e-01 | 0.1327 |
| 7850 | IL1R2 | P8T-E | Human | Esophagus | ESCC | 1.85e-13 | -5.70e-01 | 0.0889 |
| 7850 | IL1R2 | P10T-E | Human | Esophagus | ESCC | 1.23e-41 | 2.45e+00 | 0.116 |
| 7850 | IL1R2 | P12T-E | Human | Esophagus | ESCC | 1.10e-29 | -5.21e-01 | 0.1122 |
| 7850 | IL1R2 | P15T-E | Human | Esophagus | ESCC | 2.70e-17 | 2.02e+00 | 0.1149 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00109551 | Oral cavity | LP | negative regulation of protein processing | 15/4623 | 29/18723 | 1.55e-03 | 1.20e-02 | 15 |
| GO:19033181 | Oral cavity | LP | negative regulation of protein maturation | 15/4623 | 29/18723 | 1.55e-03 | 1.20e-02 | 15 |
| GO:00607592 | Oral cavity | EOLP | regulation of response to cytokine stimulus | 49/2218 | 162/18723 | 2.70e-10 | 2.45e-08 | 49 |
| GO:00019592 | Oral cavity | EOLP | regulation of cytokine-mediated signaling pathway | 46/2218 | 150/18723 | 5.71e-10 | 4.44e-08 | 46 |
| GO:001922112 | Oral cavity | EOLP | cytokine-mediated signaling pathway | 94/2218 | 472/18723 | 2.36e-07 | 7.37e-06 | 94 |
| GO:004586125 | Oral cavity | EOLP | negative regulation of proteolysis | 72/2218 | 351/18723 | 1.96e-06 | 4.49e-05 | 72 |
| GO:005160423 | Oral cavity | EOLP | protein maturation | 50/2218 | 294/18723 | 5.32e-03 | 2.77e-02 | 50 |
| GO:0060761 | Oral cavity | EOLP | negative regulation of response to cytokine stimulus | 18/2218 | 86/18723 | 1.11e-02 | 4.88e-02 | 18 |
| GO:004586133 | Oral cavity | NEOLP | negative regulation of proteolysis | 76/2005 | 351/18723 | 1.40e-09 | 9.80e-08 | 76 |
| GO:00019593 | Oral cavity | NEOLP | regulation of cytokine-mediated signaling pathway | 41/2005 | 150/18723 | 1.03e-08 | 5.12e-07 | 41 |
| GO:00607593 | Oral cavity | NEOLP | regulation of response to cytokine stimulus | 43/2005 | 162/18723 | 1.19e-08 | 5.70e-07 | 43 |
| GO:001922122 | Oral cavity | NEOLP | cytokine-mediated signaling pathway | 88/2005 | 472/18723 | 1.37e-07 | 4.80e-06 | 88 |
| GO:0001960 | Oral cavity | NEOLP | negative regulation of cytokine-mediated signaling pathway | 20/2005 | 81/18723 | 2.69e-04 | 2.71e-03 | 20 |
| GO:00607611 | Oral cavity | NEOLP | negative regulation of response to cytokine stimulus | 20/2005 | 86/18723 | 6.22e-04 | 5.33e-03 | 20 |
| GO:005160432 | Oral cavity | NEOLP | protein maturation | 50/2005 | 294/18723 | 6.46e-04 | 5.47e-03 | 50 |
| GO:001648521 | Oral cavity | NEOLP | protein processing | 39/2005 | 225/18723 | 1.68e-03 | 1.17e-02 | 39 |
| GO:0045861112 | Skin | SCCIS | negative regulation of proteolysis | 40/919 | 351/18723 | 6.58e-07 | 5.13e-05 | 40 |
| GO:007055512 | Skin | SCCIS | response to interleukin-1 | 19/919 | 143/18723 | 7.39e-05 | 1.71e-03 | 19 |
| GO:00713474 | Skin | SCCIS | cellular response to interleukin-1 | 13/919 | 113/18723 | 3.61e-03 | 3.18e-02 | 13 |
| GO:005160419 | Skin | cSCC | protein maturation | 117/4864 | 294/18723 | 1.27e-07 | 2.93e-06 | 117 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05418 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
| hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
| hsa05215 | Colorectum | AD | Prostate cancer | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
| hsa054181 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
| hsa051661 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
| hsa052151 | Colorectum | AD | Prostate cancer | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
| hsa054182 | Colorectum | SER | Fluid shear stress and atherosclerosis | 40/1580 | 139/8465 | 2.28e-03 | 1.75e-02 | 1.27e-02 | 40 |
| hsa054183 | Colorectum | SER | Fluid shear stress and atherosclerosis | 40/1580 | 139/8465 | 2.28e-03 | 1.75e-02 | 1.27e-02 | 40 |
| hsa054188 | Colorectum | FAP | Fluid shear stress and atherosclerosis | 45/1404 | 139/8465 | 3.05e-06 | 4.63e-05 | 2.81e-05 | 45 |
| hsa052152 | Colorectum | FAP | Prostate cancer | 28/1404 | 97/8465 | 1.67e-03 | 8.57e-03 | 5.21e-03 | 28 |
| hsa05202 | Colorectum | FAP | Transcriptional misregulation in cancer | 45/1404 | 193/8465 | 9.19e-03 | 3.33e-02 | 2.03e-02 | 45 |
| hsa054189 | Colorectum | FAP | Fluid shear stress and atherosclerosis | 45/1404 | 139/8465 | 3.05e-06 | 4.63e-05 | 2.81e-05 | 45 |
| hsa052153 | Colorectum | FAP | Prostate cancer | 28/1404 | 97/8465 | 1.67e-03 | 8.57e-03 | 5.21e-03 | 28 |
| hsa052021 | Colorectum | FAP | Transcriptional misregulation in cancer | 45/1404 | 193/8465 | 9.19e-03 | 3.33e-02 | 2.03e-02 | 45 |
| hsa0541839 | Esophagus | HGIN | Fluid shear stress and atherosclerosis | 42/1383 | 139/8465 | 2.92e-05 | 3.81e-04 | 3.02e-04 | 42 |
| hsa05418115 | Esophagus | HGIN | Fluid shear stress and atherosclerosis | 42/1383 | 139/8465 | 2.92e-05 | 3.81e-04 | 3.02e-04 | 42 |
| hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
| hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa0521516 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Breast | DCIS |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Cervix | ADJ |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | CRC | MSI-H |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | CRC | MSS |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Endometrium | AEH |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Endometrium | AEH |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Endometrium | EEC |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Endometrium | EEC |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Esophagus | Healthy |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | GC | ADJ |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | GC | GC |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | HNSCC | ADJ |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | HNSCC | ADJ |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | HNSCC | Healthy |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | HNSCC | OSCC |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | HNSCC | OSCC |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | HNSCC | Precancer |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | HNSCC | Precancer |
| IL1A | IL1R2 | IL1A_IL1R2 | IL1 | Lung | AAH |
| IL1B | IL1R2 | IL1B_IL1R2 | IL1 | Lung | AAH |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL1R2 | SNV | Missense_Mutation | c.88T>A | p.Phe30Ile | p.F30I | P27930 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-A2-A0T4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD | |
| IL1R2 | SNV | Missense_Mutation | rs769630697 | c.86G>A | p.Arg29Gln | p.R29Q | P27930 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| IL1R2 | SNV | Missense_Mutation | rs367683772 | c.478N>T | p.Arg160Cys | p.R160C | P27930 | protein_coding | tolerated(0.06) | possibly_damaging(0.724) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
| IL1R2 | deletion | Frame_Shift_Del | novel | c.621delT | p.Cys207TrpfsTer3 | p.C207Wfs*3 | P27930 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| IL1R2 | SNV | Missense_Mutation | c.919G>A | p.Glu307Lys | p.E307K | P27930 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| IL1R2 | SNV | Missense_Mutation | c.548N>G | p.Phe183Cys | p.F183C | P27930 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| IL1R2 | SNV | Missense_Mutation | rs759636734 | c.884N>A | p.Arg295His | p.R295H | P27930 | protein_coding | tolerated(0.16) | benign(0.037) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| IL1R2 | SNV | Missense_Mutation | novel | c.546N>C | p.Lys182Asn | p.K182N | P27930 | protein_coding | deleterious(0.04) | benign(0.323) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| IL1R2 | SNV | Missense_Mutation | rs759636734 | c.884N>A | p.Arg295His | p.R295H | P27930 | protein_coding | tolerated(0.16) | benign(0.037) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| IL1R2 | SNV | Missense_Mutation | c.13T>C | p.Tyr5His | p.Y5H | P27930 | protein_coding | tolerated(0.44) | possibly_damaging(0.459) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7850 | IL1R2 | DRUGGABLE GENOME | ANAKINRA | ANAKINRA | ||
| 7850 | IL1R2 | DRUGGABLE GENOME | IL-1 | |||
| 7850 | IL1R2 | DRUGGABLE GENOME | GSK-1827771 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |